The Next Era Of Oncology Biosimilars

Oncology biosimilars have already helped expand access to established biologic treatments while supporting more sustainable healthcare spending. As the market moves towards increasingly complex therapies, however, identifying viable opportunities will require more than monitoring patent expiries. In this podcast, ICON experts Colin Farquharson and Martin Lachs, discuss how scientific innovation, evolving standards of care and changing market dynamics are influencing the next generation of oncology biosimilars. This podcast explores: How oncology biosimilars are moving from proof of concept towards broader adoption The potential opportunities and challenges associated with antibody-drug conjugates and bispecific antibodies Why patent expiry alone is not enough to determine the long-term viability of an asset The factors influencing physician confidence, patient acceptance and market uptake How real-world evidence can strengthen confidence in biosimilar safety and efficacy The analytical, CMC, regulatory and market-planning capabilities sponsors should develop early